The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

Human papillomavirus (HPV) has been identified as the main etiological factor in the developing of cervical cancer (CC). This finding has propitiated the development of vaccines that help to prevent the HPVs 16 and 18 infection. Both genotypes are associated with 70% of CC worldwide. In the present study, we aimed to determine the emergence of high-risk nonvaccine HPV after actual vaccination scheme to estimate the impact of the current HPV vaccines. A SIR-type model was used to study the HPV dynamics after vaccination. According to the results, our model indicates that the application of the vaccine reduces infection by target or vaccine genotypes as expected. However, numerical simulations of the model suggest the presence of the phenomenon called vaccine—induced pathogen strain replacement. Here, we report the following replacement mechanism: if the effectiveness of cross-protective immunity is not larger than the effectiveness of the vaccine, then the high-risk nonvaccine genotypes emerge. In this scenario, further studies of infection dispersion by HPV are necessary to ascertain the real impact of the current vaccines, primarily because of the different high-risk HPV types that are found in CC.

Download Full-text

Recurring infection with ecologically distinct human papillomavirus (HPV) types explains high prevalence and diversity

10.1101/179341 ◽

2017 ◽

Cited By ~ 2

Author(s):

Sylvia Ranjeva ◽

Edward B. Baskerville ◽

Vanja Dukic ◽

Luisa Villa ◽

Eduardo Lazcano-Ponce ◽

...

Keyword(s):

Human Papillomavirus ◽

Transmitted Infection ◽

Sexually Transmitted ◽

Hpv Prevalence ◽

Increased Risk ◽

High Prevalence ◽

Hpv Types ◽

One Year ◽

The One ◽

The Impact

AbstractThe high prevalence of human papillomavirus (HPV), the most common sexually transmitted infection, arises from the coexistence of over 200 genetically distinct types. Accurately predicting the impact of vaccines that target multiple types requires understanding the factors that determine HPV diversity. The diversity of many pathogens is driven by type-specific or “homologous” immunity, which promotes the spread of variants to which hosts have little immunity. To test for homologous immunity and to identify mechanisms determining HPV transmission, we fitted nonlinear mechanistic models to longitudinal data on genital infections in unvaccinated men. Our results provide no evidence for homologous immunity, instead showing that infection with one HPV type strongly increases the risk of infection with that type for years afterwards. For HPV16, the type responsible for most HPV-related cancers, an initial infection increases the one-year probability of reinfection by 20-fold, and the probability of reinfection remains 14-fold higher two years later. This increased risk occurs in both sexually active and celibate men, suggesting that it arises from auto-inoculation, episodic reactivation of latent virus, or both. Overall our results show that high HPV prevalence and diversity can be explained by a combination of a lack of homologous immunity, frequent reinfections, weak competition between types, and variation in type fitness between host subpopulations. Due to the high risk of reinfection, vaccinating boys that have not yet been exposed may be crucial to reduce prevalence, but our results suggest that there may also be large benefits from vaccinating previously infected individuals.

Download Full-text

Prevalence of Oral Human Papillomavirus Infection among Indian HIV-Positive Men Who Have Sex With Men: A Cross-Sectional Study

10.21203/rs.3.rs-60960/v1 ◽

2020 ◽

Author(s):

Alexandra Lydia Hernandez ◽

Rajiv Karthik ◽

Murugesan Sivasubramanian ◽

Anantharam Raghavendran ◽

Shelly Lensing ◽

...

Keyword(s):

Human Papillomavirus ◽

Hpv Infection ◽

Sexual History ◽

Hiv Positive ◽

Increased Risk ◽

Oral Hpv ◽

Hpv Types ◽

Sex With Men ◽

The Impact ◽

Hiv Positive Men

Abstract Background: Oral human papillomavirus (HPV) infection has been causally linked to a subset of oropharyngeal cancers in Western populations15-20, and both oropharyngeal cancer and oral HPV infection are increased among HIV-positive individuals24,41. India has high incidences of oral and oropharyngeal cancers, and Indian HIV-positive men who have sex with men (MSM) may be at increased risk of developing oropharyngeal cancers. However, there is little information available on the prevalence of oral HPV in this population.Methods: We tested 302 HIV-positive Indian MSM for oral HPV infection using L1 HPV DNA PCR with probes specific for 29 types and a mixture of 10 additional types. CD4+ level and plasma HIV viral load (VL) were measured. Participants completed an interviewer-administered questionnaire including a sexual history.Results: The prevalence of oral HPV was 23.7% (95% CI: 19-29%) and 2.4% of participants had oncogenic HPV types. No participants had oral HPV type 16 (HPV-16) and the prevalence of other anogenital HPV types was low. Participants with higher CD4+ levels had reduced odds of having any oral HPV infection (OR: 3.1 [1.4-6.9]) in multivariable analyses.Conclusions: This is the first report of oral HPV among Indian HIV-positive MSM. Our results show a high prevalence of oral HPV infection consistent with studies from Western populations. However, oncogenic anogenital HPV types were relatively uncommon in our study population. It is unknown what the impact of this distribution of oral HPV will be on oropharyngeal cancers. HIV-positive MSM in India should be monitored closely for oral and oropharyngeal pre-cancer and cancer.

Download Full-text

Efficacy of a quadrivalent HPV (types 6/11/16/18) L1 virus-like particle (VLP) vaccine against vaginal and vulvar pre-cancerous lesions: a combined analysis

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.5011 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 5011-5011 ◽

Cited By ~ 5

Author(s):

J. Paavonen

Keyword(s):

Placebo Group ◽

Precancerous Lesions ◽

Hpv 16 ◽

Combined Analysis ◽

Younger Women ◽

Intention To Treat ◽

Virus Like Particle ◽

Hpv Types ◽

The Impact

5011 Background: In the US, 6000 cases of vulvar or vaginal cancer are diagnosed annually. HPV is detected in 75–100% of vulvar cancers in younger women. The most common HPV type detected is HPV 16, followed by HPV 18. These two types also cause a majority of HPV-related vaginal cancers. Treatment to prevent progression to vaginal/vulvar cancer is challenging. Here, we present a combined analysis of 3 randomized, placebo-controlled trials to evaluate the impact of a prophylactic quadrivalent HPV vaccine on the rates of HPV 16- and 18-related vulvar and vaginal neoplasia grade 2/3 (VIN 2/3 and VaIN 2/3). Methods: 18,150 women (16–26 yrs) from the Americas, Europe and Asia were enrolled in 1 of 3 trials. Subjects were randomized to either quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP vaccine or placebo. For all trials, vaccination occurred at day 1, and months 2 and 6. Genital tract specimens were obtained at day 1 and at 6–12 month intervals thereafter for a maximum of 48 months. Colposcopy referral was algorithm-based. Biopsies were HPV-typed. Cytology, histology, and HPV detection were conducted centrally. Analyses were done per protocol (PP) (subjects received 3 doses, had no major protocol violations, were HPV 16 or 18 seronegative at Day 1 and HPV 16 or 18 DNA negative Day 1 through month 7) and modified intention to treat (MITT) (received ≥1 dose and were HPV 16 or 18 negative at Day 1 by serology and DNA). Endpoint counts began after Month 7 and Day 30 in the PP and MITT analyses, respectively. Results: In PP analysis, after an average of 18 months of follow-up, the vaccine was 100% effective (95% CI: 56–100%) in preventing HPV 16- or 18-related VIN 2/3 or VaIN 2/3. There were 10 cases in the placebo group and 0 cases in the vaccine group. In the MITT population, after an average of 2 years of follow-up, there were 24 histologically confirmed cases of HPV 16- or 18-related VIN 2/3 or VaIN 2/3, all in the placebo group (100% efficacy; 95% CI: 83–100%). Conclusions: Quadrivalent HPV VLP vaccine prevented HPV 16 and 18-related vaginal and vulvar high-grade precancerous lesions for at least 2 years post-immunization. This intervention is expected to greatly reduce the risk of vulvar and vaginal cancers. [Table: see text]

Download Full-text

The impact of human papillomavirus (HPV) types 6, 11 in women with genital warts

Archives of Gynecology and Obstetrics ◽

10.1007/s00404-012-2416-1 ◽

2012 ◽

Vol 286 (5) ◽

pp. 1261-1267 ◽

Cited By ~ 6

Author(s):

Mahin Jamshidi ◽

Mohammad Shekari ◽

Abdol Azim Nejatizadeh ◽

Keyanoush Malekzadeh ◽

Mahnaz Baghershiroodi ◽

...

Keyword(s):

Human Papillomavirus ◽

Genital Warts ◽

Hpv Types ◽

The Impact

Download Full-text

The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/j.1468-3083.2009.03266.x ◽

2009 ◽

Vol 23 (10) ◽

pp. 1147-1155 ◽

Cited By ~ 19

Author(s):

S Majewski ◽

FX Bosch ◽

J. Dillner ◽

O-E Iversen ◽

SK Kjaer ◽

...

Keyword(s):

Human Papillomavirus ◽

Virus Like Particle ◽

The Impact ◽

European Women

Download Full-text

Human Papillomavirus (HPV) L1 and L1-L2 Virus-Like Particle-Based Multiplex Assays for Measurement of HPV Virion Antibodies

Clinical and Vaccine Immunology ◽

10.1128/cvi.00191-12 ◽

2012 ◽

Vol 19 (9) ◽

pp. 1348-1352 ◽

Cited By ~ 10

Author(s):

Brenda Y. Hernandez ◽

Thien Ton ◽

Yurii B. Shvetsov ◽

Marc T. Goodman ◽

Xuemei Zhu

Keyword(s):

Human Papillomavirus ◽

Adult Males ◽

Substantial Agreement ◽

Serologic Test ◽

Multiplex Assays ◽

Large Numbers ◽

Virus Like Particle ◽

Hpv Types ◽

Males And Females ◽

Serologic Assay

ABSTRACTHumoral immunity to human papillomavirus (HPV) has not been fully characterized, and there is currently no standard serologic test for the measurement of HPV antibodies. Most HPV serologic assays developed to date are based on virus-like particles (VLPs) of the major HPV capsid protein, L1. We sought to compare the performance of a multiplex HPV L1 VLP-based serologic assay to that of an assay based on VLPs comprised of both L1 and the minor capsid, L2. We developed HPV L1 VLP and L1-L2 VLP-based multiplex seroassays for the detection of HPV type 16 (HPV16) and HPV18 virion binding antibodies using Luminex fluorescent bead technology. We compared the performance of these assays to that of established pseudovirion-based neutralization and L1 VLP-based enzyme-linked immunosorbent assays (ELISAs).A total of 391 serum specimens from unvaccinated adult males and females were tested. The L1 and L1-L2 VLP multiplex seroassays each demonstrated substantial agreement with both the neutralization assays and the ELISAs for the detection of HPV16 antibodies (κ = 0.60 to 0.64). However, the L1-L2 VLP seroassay demonstrated better agreement with neutralization assays for the detection of HPV18 antibodies than the L1 VLP seroassay (κ = 0.74 and 0.43, respectively). L1 and L1-L2 VLP seroassays showed excellent agreement with one another for the detection of HPV16 antibodies (κ = 0.86) but only moderate agreement for HPV18 antibodies (κ = 0.44). The HPV L1-L2 VLP seroassay performs well for the concurrent measurement of HPV16 and -18 antibodies in large numbers of samples and may be extended to include other HPV types.

Download Full-text

High human papillomavirus prevalence among females attending high school in the Eastern Cape Province of South Africa

PLoS ONE ◽

10.1371/journal.pone.0253074 ◽

2021 ◽

Vol 16 (6) ◽

pp. e0253074

Author(s):

Zizipho Z. A. Mbulawa ◽

Nontuthuzelo I. Somdyala ◽

Sikhumbuzo A. Mabunda ◽

Anna-Lise Williamson

Keyword(s):

South Africa ◽

Human Papillomavirus ◽

African Ancestry ◽

Vaccination Strategy ◽

Hpv Infection ◽

Eastern Cape Province ◽

Eastern Cape ◽

Hpv Prevalence ◽

Hpv Types ◽

The Impact

As part of the human papillomavirus (HPV) vaccination strategy in South Africa, it is essential to have information on HPV prevalence, and HPV types distribution among the unvaccinated population. Information on the prevalence of HPV and the distribution of HPV types in adolescents and young women in South Africa’s Eastern Cape Province is minimal. Therefore, this study investigates the prevalence, distribution of HPV types, and factors associated with HPV infection amongst unvaccinated female learners. A sample composed of 213 sexually active female learners attending high schools in the Eastern Cape Province of South Africa; median age 18 years, who provided self-collected vaginal specimens. Roche Linear Array HPV genotyping assay that detects 37 HPV genotypes was used to detect HPV infection. HPV infection was detected in 76.06% (162/213) of participants. Of these 14.55% (31/213) were positive for HPV types targeted by the Cervarix® HPV vaccine (HPV-16 and/or 18), 20.66% (44/213) by Gardasil®4 (HPV-6, -11, -16 and/or -18) and 37.09% (79/213) by Gardasil®9 (HPV-6, -11, -16, -18, -31, -33, -45, -52 and/or -58). HPV-35, commonly detected in cervical cancer cases among women of African ancestry, was frequently detected (9.40%). Participants who reported to have ever consumed alcohol had a significantly higher risk of HPV infection (OR: 2.91, 95% CI: 1.38–6.11, p = 0.005). High HPV prevalence was observed among participants. The high prevalence of HPV types targeted by the Gardasil®9 vaccine encourages the introduction of the Gardasil®9 vaccine. Data from this study will inform both vaccination campaigns and monitor the impact on HPV types after vaccination.

Download Full-text

Prevalence of Oral Human Papillomavirus Infection among Indian HIV-positive Men who have Sex with Men: A Cross-Sectional Study

10.21203/rs.3.rs-60960/v2 ◽

2021 ◽

Author(s):

Alexandra Lydia Hernandez ◽

Rajiv Karthik ◽

Murugesan Sivasubramanian ◽

Anantharam Raghavendran ◽

Shelly Lensing ◽

...

Keyword(s):

Human Papillomavirus ◽

Hpv Infection ◽

Sexual History ◽

Hiv Positive ◽

Increased Risk ◽

Oral Hpv ◽

Hpv Types ◽

Sex With Men ◽

The Impact ◽

Hiv Positive Men

Abstract Background: Oral human papillomavirus (HPV) infection has been causally linked to a subset of oropharyngeal cancers in Western populations15-20, and both oropharyngeal cancer and oral HPV infection are increased among HIV-positive individuals24,41. India has high incidences of oral and oropharyngeal cancers, and Indian HIV-positive men who have sex with men (MSM) may be at increased risk of developing oropharyngeal cancers. However, there is little information available on the prevalence of oral HPV in this population.Methods: We tested 302 HIV-positive Indian MSM for oral HPV infection using L1 HPV DNA PCR with probes specific for 29 types and a mixture of 10 additional types. CD4+ level and plasma HIV viral load (VL) were measured. Participants completed an interviewer-administered questionnaire including a sexual history.Results: The prevalence of oral HPV was 23.7% (95% CI: 19-29%) and 2.4% of participants had oncogenic HPV types. No participants had oral HPV type 16 (HPV-16) and the prevalence of other anogenital HPV types was low. Participants with higher CD4+ levels had reduced odds of having any oral HPV infection (OR: 3.1 [1.4-6.9]) in multivariable analyses. Conclusions: This is the first report of oral HPV among Indian HIV-positive MSM. Our results show a high prevalence of oral HPV infection consistent with studies from Western populations. However, oncogenic anogenital HPV types were relatively uncommon in our study population. It is unknown what the impact of this distribution of oral HPV will be on oropharyngeal cancers. HIV-positive MSM in India should be monitored closely for oral and oropharyngeal pre-cancer and cancer.

Download Full-text